Hummingbird Bioscience, a homegrown leading biotech company backed by investors including Heritas Capital and SEEDS Capital, has achieved a significant milestone with the approval from Singapore Health Sciences Authority (HSA) to initiate clinical trial to study the safety and efficacy of its experimental SARS-CoV-2 antibody therapy, HMBD-115.

Amongst various key findings, pre clinical data has demonstrated significant therapeutic benefit for HMBD-115 as a potent neutralizing antibody that has been highly efficacious in multiple models of COVID-19. Phase I/II clinical trial of HMBD-115 is ongoing with early read-out expected in December 2020. A Phase III trial is scheduled for the end of 2020.

“We are pleased that Hummingbird Bioscience has successfully collaborated with global and local scientific partners to develop a Covid-19 antibody treatment, and is now ready for clinical trials, marking a new milestone as it enters clinical development stage. This achievement has come atop the commitment to existing main discovery and development programs before Covid-19 pandemic hits us. However, a sense of mission and purpose has united shareholders, founders, management team and staff towards finding a cure for Covid-19 patients in a short timeframe, demonstrating the deep scientific and development capabilities of the team”, said Chik Wai Chiew, Executive Director and CEO of Heritas Capital as well as Board Director at Hummingbird Bioscience.

More information can be found at Hummingbird Bioscience